Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study

Autor: Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez, Alfonso Lagares, Michael Mokry, Harald Willschke, Charlotte Flüh, Erich Schmutzhard, on behalf of the NOSTRA Investigators

Publikováno v: Trials, Vol 21, Iss 1, Pp 1-9 (2020)

Abstract Background Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial. Methods/design Th

Externí odkaz: https://doaj.org/article/44e95a0f074d4a7cb95f8631885ef9de

Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study (vol 21, 80, 2020)

Autor: Tegtmeier, Frank, Schinzel, Reinhard, Beer, Ronny, Bulters, Diederik, LeFrant, Jean-Yves, Sahuquillo, Joan, Unterberg, Andreas, Andrews, Peter, Belli, Antonio, Ibanez, Javier, Lagares, Alfonso, Mokry, Michael, Willschke, Harald, Flueh, Charlotte, Schmutzhard, Erich, NOSTRA Investigators

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10449::7c5302f8c5142c04d1e6d6055ee274dd
https://hdl.handle.net/20.500.13003/11699

Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study.

Autor: Tegtmeier F; vasopharm GmbH, Würzburg, Germany., Schinzel R; vasopharm GmbH, Würzburg, Germany. schinzel@vasopharm.de., Beer R; Medizinische Universität Innsbruck, Innsbruck, Austria., Bulters D; Wessex Neurological Centre University Hospital, Southampton, UK., LeFrant JY; Hopital Universitaire Caremeau, Nimes, France., Sahuquillo J; Vall d'Hebron University Hospital, Barcelona, Spain., Unterberg A; Universitätsklinikum Heidelberg, Heidelberg, Germany., Andrews P; Western General Hospital Lothian University, Edinburgh, UK., Belli A; Queen Elizabeth Hospital, Birmingham, UK., Ibanez J; Espases University Hospital, Palma de Mallorca, Spain., Lagares A; Hospital Universitario 12 de Octubre, Madrid, Spain., Mokry M; LKH - Universitätsklinikum Graz, Graz, Austria., Willschke H; Medizinische Universität Wien, Wien, Austria., Flüh C; Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Schmutzhard E; Medizinische Universität Innsbruck, Innsbruck, Austria.

Publikováno v: Trials [Trials] 2020 Feb 12; Vol. 21 (1), pp. 172. Date of Electronic Publication: 2020 Feb 12.

Coadministration of Ketamine and Perampanel Improves Behavioral Function and Reduces Inflammation in Acute Traumatic Brain Injury Mouse Model.

Autor: Alqahtani, Faleh¹ (AUTHOR), Assiri, Mohammed A.¹ (AUTHOR), Mohany, Mohamed¹ (AUTHOR), Imran, Imran² (AUTHOR), Javaid, Sana^2,3 (AUTHOR), Rasool, Muhammad Fawad⁴ (AUTHOR), Shakeel, Waleed² (AUTHOR), Sivandzade, Farzane⁵ (AUTHOR), Alanazi, Ahmed Z.¹ (AUTHOR), Al-Rejaie, Salim S.¹ (AUTHOR), Alshammari, Musaad A.¹ (AUTHOR), Alasmari, Fawaz¹ (AUTHOR), Alanazi, Mohammed Mufadhe¹ (AUTHOR), Alamri, Faisal F.^6,7 (AUTHOR)

Publikováno v: BioMed Research International. 12/16/2020, p1-12. 12p.

Insights on Localized and Systemic Delivery of Redox-Based Therapeutics.

Autor: Buglak, Nicholas E., Batrakova, Elena V., Mota, Roberto, Bahnson, Edward S. M.

Publikováno v: Oxidative Medicine & Cellular Longevity; 2/14/2018, p1-23, 23p